Progress in molecular-based management of differentiated thyroid cancer
Top Cited Papers
- 1 March 2013
- journal article
- research article
- Published by Elsevier in The Lancet
- Vol. 381 (9871) , 1058-1069
- https://doi.org/10.1016/s0140-6736(13)60109-9
Abstract
No abstract availableFunding Information
- National Institutes of Health (R01CA113507, R01CA134225)
- Institut National Du Cancer
This publication has 126 references indexed in Scilit:
- Preoperative Diagnosis of Benign Thyroid Nodules with Indeterminate CytologyNew England Journal of Medicine, 2012
- Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trialThe Lancet Oncology, 2012
- Strategies of Radioiodine Ablation in Patients with Low-Risk Thyroid CancerNew England Journal of Medicine, 2012
- MicroRNA Signature in Thyroid Fine Needle Aspiration Cytology Applied to “Atypia of Undetermined Significance” CasesThyroid®, 2012
- Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium studyThe Lancet Oncology, 2010
- Inhibition of Mutated, Activated BRAF in Metastatic MelanomaNew England Journal of Medicine, 2010
- Molecular Testing for Somatic Mutations Improves the Accuracy of Thyroid Fine‐needle Aspiration BiopsyWorld Journal of Surgery, 2010
- Genetic Alterations in the Phosphatidylinositol-3 Kinase/Akt Pathway in Thyroid CancerThyroid®, 2010
- Prognostic utility of BRAF mutation in papillary thyroid cancerMolecular and Cellular Endocrinology, 2010
- Papillary MicrocarcinomaWorld Journal of Surgery, 2008